TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6348587

Group type: EXPERIMENTAL
Intervention: Nadolol, 120 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nadolol, 240 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30472778

Group type: EXPERIMENTAL
Intervention: HF‐rTMS (20 Hz)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: iTBS
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 34
Study: 29529475

Group type: EXPERIMENTAL
Intervention: Exercise Group (EG)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 508
Study: 26767373

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Balanced amino acid load (BAL)
Number of subjects: 18
Study: 24789625

Group type: EXPERIMENTAL
Intervention: Massachusetts health reform enacted in 2006
Number of subjects: 208831
Study: 21551318

Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel (LA) 60, 90, or 120 mg every 28 days
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel (LA) 120 mg
Number of subjects: 104
Study: 20617456

Group type: EXPERIMENTAL
Intervention: n‐3‐PSE
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 91
Study: 17548021

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy targeting glucose range of 5 to 7 mmol/L
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy targeting glucose range of 8 to 10 mmol/L
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 20
Study: 15846111

Group type: EXPERIMENTAL
Intervention: LY293111
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 0
Study: 12081234

Group type: EXPERIMENTAL
Intervention: Conventional hMG-hCG method
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: hMG step-down method
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sequential hMG-GnRH method
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Modified hMG-GnRH method
Number of subjects: 20
Study: 10443063

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg once daily, adjusted to 100 mg if necessary)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Extended-release felodipine (5 mg once daily, adjusted to 10 mg if necessary)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Extended-release felodipine (5 mg once daily)
Number of subjects: 44
Study: 8991995

Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg three times daily
Number of subjects: 812

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid 300 mg twice daily
Number of subjects: 812
Study: 28244890

Group type: EXPERIMENTAL
Intervention: Otago Exercise Program (OEP)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: OEP combined with Motivational Interviewing (MI)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 175
Study: 28145919

Group type: EXPERIMENTAL
Intervention: 1-minute rest interval (G-1 min)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 3-minute rest interval (G-3 min)
Number of subjects: 21
Study: 25887099

Group type: EXPERIMENTAL
Intervention: Selumetinib 75mg PO BID administered daily until progression or intolerance, one cycle was 28 days.
Number of subjects: 52
Study: 22926324

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mL/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 15
Study: 21487148

Group type: EXPERIMENTAL
Intervention: 4 g/d of L-leucine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Lactose (placebo)
Number of subjects: 26
Study: 19653973

Group type: EXPERIMENTAL
Intervention: Novo-venlafaxine XR 75 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Effexor XR 75 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gen-citalopram 40 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Celexa 40 mg
Number of subjects: 12
Study: 17559852

Group type: EXPERIMENTAL
Intervention: High salivary testosterone levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low salivary testosterone levels
Number of subjects: 0
Study: 15302319

Group type: EXPERIMENTAL
Intervention: Prostaglandin E(2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ibuprofen (antiprostaglandin)
Number of subjects: 20
Study: 11598430

Group type: EXPERIMENTAL
Intervention: Experiential-existential group psychotherapy (EEGP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control (WLC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EEGP
Number of subjects: 0

Group type: COMPARATOR
Intervention: WLC
Number of subjects: 0
Study: 9486567

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (two cycles of cisplatin, vincristine, peplomycin, with or without mitomycin C)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Number of subjects: 141

Group type: COMPARATOR
Intervention: Surgery with or without peplomycin chemotherapy (Group A)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Preoperative radiotherapy with or without concomitant peplomycin chemotherapy followed by surgery (Group B)
Number of subjects: 141
Study: 8018525

Group type: EXPERIMENTAL
Intervention: Intratumoral recombinant interferon gamma (rIFN-gamma)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (subcutaneous reservoir of rIFN-gamma injections)
Number of subjects: 31
Study: 2555713

Group type: EXPERIMENTAL
Intervention: 3,4-Diaminopyridine (up to 100 mg per day)
Number of subjects: 12
Study: 818490

Group type: EXPERIMENTAL
Intervention: Perhexiline maleate
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30701368

Group type: EXPERIMENTAL
Intervention: Onlay mesh (group A)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard abdominal wall closure (no mesh, group B)
Number of subjects: 160
Study: 28482639

Group type: EXPERIMENTAL
Intervention: Chinese calligraphy writing training (n = 48)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (tablet computer training) (n = 51)
Number of subjects: 99
Study: 25203489

Group type: EXPERIMENTAL
Intervention: Shock Wave Lithotripsy (SWL)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Flexible Ureterorenoscopy (RIRS)
Number of subjects: 195
Study: 24012146

Group type: EXPERIMENTAL
Intervention: Selenium-silymarin mix (240μg selenium plus 570mg silymarin daily for 6 months)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 20888671

Group type: EXPERIMENTAL
Intervention: Preservative-free propofol infusion
Number of subjects: 523

Group type: COMPARATOR
Intervention: No propofol
Number of subjects: 523
Study: 18972786

Group type: EXPERIMENTAL
Intervention: Groups A1 and B1 (irradiated dentin surface with GIC placed after irradiation)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Groups A2 and B2 (GIC placed on dentin surface before irradiation)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Groups C1 and C2 (non-irradiated controls)
Number of subjects: 30
Study: 16525231

Group type: EXPERIMENTAL
Intervention: Boostrix (reduced‐antigen diphtheria‐tetanus‐acellular pertussis)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Tetavax (licensed monovalent tetanus‐toxoid vaccine)
Number of subjects: 320
Study: 13679719

Group type: EXPERIMENTAL
Intervention: Handipark score
Number of subjects: 30
Study: 10634404

Group type: EXPERIMENTAL
Intervention: GAD65Ab positive subjects (61/569, 10.7%)
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: GAD65-CAb in insulin-treated subjects
Number of subjects: 569

Group type: COMPARATOR
Intervention: GAD65-CAb in subjects treated with hypoglycemic agents and/or diet
Number of subjects: 569

Group type: COMPARATOR
Intervention: GAD65-MAb in subjects treated with hypoglycemic agents and/or diet
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: GAD65-CAb
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: GAD65-M+CAb
Number of subjects: 569

Group type: COMPARATOR
Intervention: GAD65-MAb only
Number of subjects: 569
Study: 9374965

Group type: EXPERIMENTAL
Intervention: Gowning status (gown)
Number of subjects: 895

Group type: COMPARATOR
Intervention: Non-gown status (no gown)
Number of subjects: 895

Group type: EXPERIMENTAL
Intervention: Younger patients
Number of subjects: 895

Group type: EXPERIMENTAL
Intervention: Patients seeing a doctor for the first time
Number of subjects: 895
Study: 1312556

Group type: EXPERIMENTAL
Intervention: Fish oil and low sodium
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Sunflower oil and low sodium
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Fish oil and normal sodium
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Sunflower oil and normal sodium
Number of subjects: 106
Study: 2858842

Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 30692018

Group type: EXPERIMENTAL
Intervention: BodyPump (high-repetition low-load group session)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Heavy load resistance training with a personal trainer
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Non-supervised heavy load resistance training
Number of subjects: 92

Group type: COMPARATOR
Intervention: Non-exercising controls
Number of subjects: 92
Study: 29503112

Group type: EXPERIMENTAL
Intervention: 1 dose of MenACWY-TT at month 0 (ACWY_1)
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: 2 doses of MenACWY-TT at month 0 and month 2 (ACWY_2)
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: MenACWY-TT and PCV13 co-administered at month 0 (Co-ad)
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: PCV13 at month 0 and MenACWY-TT at month 2 (PCV13/ACWY)
Number of subjects: 802

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 802
Study: 26896121

Group type: EXPERIMENTAL
Intervention: Positive Outlook Program (7-week online self-management program)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 132
Study: 24666176

Group type: EXPERIMENTAL
Intervention: Levosert(®)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Mirena(®)
Number of subjects: 280
Study: 22571245

Group type: EXPERIMENTAL
Intervention: Expressive talking intervention (EE)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 58
Study: 20478097

Group type: EXPERIMENTAL
Intervention: RUD-FOCA (Resource Utilization in Dementia - Formal Care)
Number of subjects: 148
Study: 17476596

Group type: EXPERIMENTAL
Intervention: IV remifentanil (group B)
Number of subjects: 116

Group type: COMPARATOR
Intervention: IV midazolam and pethidine (group A)
Number of subjects: 116
Study: 15188106

Group type: EXPERIMENTAL
Intervention: Zwey‐Muller cementless total hip arthroplasty (THA)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Corail cementless total hip arthroplasty (THA)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Optifix cementless total hip arthroplasty (THA)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Autophor 900S cementless total hip arthroplasty (THA)
Number of subjects: 80
Study: 12218423

Group type: EXPERIMENTAL
Intervention: Risperidone (0.02 to 0.06 mg/kg per day)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 110
Study: 9832297

Group type: EXPERIMENTAL
Intervention: Dipyrone (two 0.5-g tablets)
Number of subjects: 28
Study: 8076441

Group type: EXPERIMENTAL
Intervention: Topical 2% sodium fusidate ointment applied in the anterior nares and in the pericatheter skin twice daily for 5 days
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Oral ofloxacin 200 mg taken every 48 hours for 5 days
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 2518898

Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum and group sessions (n = 37)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo group with identical intervention (n = 38)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum with follow-up in the consulting room (n = 31)
Number of subjects: 106
Study: 1195474

Group type: EXPERIMENTAL
Intervention: Sulfacytine 1 gm daily for 10 days
Number of subjects: 98

Group type: COMPARATOR
Intervention: Sulfisoxazole 4 gm daily for 10 days
Number of subjects: 98
Study: 31444776

Group type: EXPERIMENTAL
Intervention: Extended pouch RYGB (EP-GB)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard pouch RYGB (S-GB)
Number of subjects: 132
Study: 31274193

Group type: EXPERIMENTAL
Intervention: Automatic contour validation using a decision tree model based on texture features from the core subregion.
Number of subjects: 55

Group type: COMPARATOR
Intervention: Ground-truth contours for comparison.
Number of subjects: 55
Study: 29857884

Group type: EXPERIMENTAL
Intervention: Shiatsu + physical activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical activity alone
Number of subjects: 0
Study: 27149410

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Schema therapy
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Appetite-focused cognitive-behavioural therapy
Number of subjects: 112
Study: 24556773

Group type: EXPERIMENTAL
Intervention: Supportive department/division culture
Number of subjects: 133

Group type: COMPARATOR
Intervention: Heavy work demands
Number of subjects: 133
Study: 22539562

Group type: EXPERIMENTAL
Intervention: TEC (paclitaxel/carboplatin/epirubicin; 75 mg/m2 i.v.)
Number of subjects: 887

Group type: COMPARATOR
Intervention: TC (paclitaxel/carboplatin; AUC 5 and 175 mg/m2)
Number of subjects: 887

Group type: EXPERIMENTAL
Intervention: TEC
Number of subjects: 887

Group type: COMPARATOR
Intervention: TC
Number of subjects: 887
Study: 20181996

Group type: EXPERIMENTAL
Intervention: 20 min of walking (exercise)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sitting quietly (control)
Number of subjects: 0
Study: 17616446

Group type: EXPERIMENTAL
Intervention: Smoking-related T2s
Number of subjects: 55

Group type: COMPARATOR
Intervention: Neutral T2s
Number of subjects: 55
Study: 15616084

Group type: EXPERIMENTAL
Intervention: 50 microg of morphine
Number of subjects: 65

Group type: COMPARATOR
Intervention: 0.05 mL of saline (control group)
Number of subjects: 65
Study: 11874412

Group type: EXPERIMENTAL
Intervention: 1 microg/kg CRH
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 2 microg/kg CRH
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 10360204

Group type: COMPARATOR
Intervention: Hydroxyzine (HYZ) 3.7 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hydroxyzine (HYZ) 3.7 mg/kg + Metoclopramide (MTP) 5 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hydroxyzine (HYZ) + Metoclopramide (MTP)
Number of subjects: 30
Study: 7865500

Group type: EXPERIMENTAL
Intervention: Adjunctive treatment with the anticholinergic biperiden
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 1827005

Group type: EXPERIMENTAL
Intervention: Isradipine 1.25 mg or 2.5 mg twice daily orally for one year
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Isradipine with beta-blocker bopindolol
Number of subjects: 23
Study: 6808225

Group type: EXPERIMENTAL
Intervention: Oral antibiotics (neomycin, colistin, and nystatin) in conventional ward isolation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strict isolation, filtered air, sterilized food and oral antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: No antimicrobial suppression but conventional ward isolation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotics for gut flora suppression in conventional ward isolation
Number of subjects: 0
Study: 31090746

Group type: EXPERIMENTAL
Intervention: Trans-sinus implants without simultaneous bone grafting (group 1, n = 16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Trans-sinus implants with sinus elevation procedures and bone grafting (group 2, n = 16)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Trans-sinus implants without simultaneous bone grafting (group 1)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Trans-sinus implants with sinus elevation procedures and bone grafting (group 2)
Number of subjects: 32
Study: 28294200

Group type: EXPERIMENTAL
Intervention: Immediate implants
Number of subjects: 42

Group type: COMPARATOR
Intervention: Delayed implants
Number of subjects: 42

Group type: COMPARATOR
Intervention: Maxilla implants
Number of subjects: 42

Group type: COMPARATOR
Intervention: Mandible implants
Number of subjects: 42

Group type: COMPARATOR
Intervention: Immediate and delayed implants
Number of subjects: 42

Group type: COMPARATOR
Intervention: Mandibular implants
Number of subjects: 42
Study: 25882325

Group type: EXPERIMENTAL
Intervention: Brexpiprazole 2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brexpiprazole 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24461797

Group type: EXPERIMENTAL
Intervention: Huntington's disease participants
Number of subjects: 11

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Huntington's disease participants and matched controls
Number of subjects: 11
Study: 22836511

Group type: EXPERIMENTAL
Intervention: Carboplatin-pegylated liposomal doxorubicin (CD)
Number of subjects: 976

Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel (CP)
Number of subjects: 976
Study: 20961738

Group type: EXPERIMENTAL
Intervention: Induced hypotensive anaesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normotensive anaesthesia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Induced hypotensive anaesthesia combined with isovolaemic haemodilution
Number of subjects: 60
Study: 17514539

Group type: EXPERIMENTAL
Intervention: 1,500 kcal/day free‐snack program
Number of subjects: 32

Group type: COMPARATOR
Intervention: 1,500 kcal/day restricted‐snack program
Number of subjects: 32
Study: 15886837

Group type: EXPERIMENTAL
Intervention: Scaling and teeth brushing with YAHAO toothpaste (eugenol and borax cream)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 48
Study: 11964594

Group type: EXPERIMENTAL
Intervention: Breathing oxygen with Pao2 increased to 406 +/- 47 mmHg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Breathing room air at hemoglobin concentration of 5.7 +/- 0.3 g/dl
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control tests without alteration of hemoglobin concentration
Number of subjects: 31
Study: 10213010

Group type: EXPERIMENTAL
Intervention: irinotecan (350 mg/m2 every 3 weeks)
Number of subjects: 267

Group type: COMPARATOR
Intervention: infusional 5-FU
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: irinotecan
Number of subjects: 267
Study: 8545528

Group type: EXPERIMENTAL
Intervention: Clonidine (CLO)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Haloperidol (HAL)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Diazepam (DZP)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Low-tryptophan drink (Lo-TRP)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 1693204

Group type: EXPERIMENTAL
Intervention: VVIR mode (activity responsive rate variable ventricular pacing)
Number of subjects: 14

Group type: COMPARATOR
Intervention: DDD mode (dual chamber pacing at 80 beats/min)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: VVIR mode
Number of subjects: 14

Group type: COMPARATOR
Intervention: DDD mode
Number of subjects: 14
Study: 7018853

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (CFX)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 18
Study: 31514054

Group type: EXPERIMENTAL
Intervention: Chronic benzodiazepine users (n = 47)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Nonusers (n = 221)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Short-acting BZDs
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Long-acting BZDs
Number of subjects: 268
Study: 28849804

Group type: EXPERIMENTAL
Intervention: SonicFill (Kerr) with single-component self-etch adhesive system
Number of subjects: 30

Group type: COMPARATOR
Intervention: Incrementally placed conventional posterior composite resin (Herculite Ultra, Kerr)
Number of subjects: 30
Study: 26489051

Group type: EXPERIMENTAL
Intervention: Proprietary blend of ancient peat and apple extracts (TRT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 25
Study: 23379651

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) with metformin
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: rFSH with metformin
Number of subjects: 165

Group type: COMPARATOR
Intervention: rFSH only (Control group)
Number of subjects: 165
Study: 17933162

Group type: EXPERIMENTAL
Intervention: 10 microg x kg(‐1) caudal morphine
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 15 microg x kg(‐1) caudal morphine
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 30 microg x kg(‐1) caudal morphine
Number of subjects: 135
Study: 14729792

Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 60
Study: 10740331

Group type: EXPERIMENTAL
Intervention: 1.5 mg piperazine oestrone sulphate + 0.7 mg norethisterone (highEP)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 0.75 mg piperazine oestrone sulphate + 0.35 mg norethisterone (lowEP)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 2 mg 17 beta‐oestradiol continuously combined with 1 mg norethisterone acetate (E2+NETA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: All hormone groups (highEP, lowEP, E2+NETA)
Number of subjects: 200
Study: 9360156

Group type: EXPERIMENTAL
Intervention: HeartPak Portable Pneumatic Driver
Number of subjects: 7

Group type: COMPARATOR
Intervention: HeartMate 1000 (conventional driver)
Number of subjects: 7
Study: 8472696

Group type: EXPERIMENTAL
Intervention: Carbohydrate drink (5.0 ml.kg‐1 body weight of a 19.7% carbohydrate drink)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carbohydrate drink and Placebo
Number of subjects: 10